financial planned XXX of program towards represented you to urinary Initiation quarter underscoring quarter achieving Jim. indication. focus this call. stress milestone advancing and Thanks, today completion Good potential randomization thank Jim subjects everyone. capital strong maintains of continuing my position our incontinence just of pivotal our future company I'd organization, critical the remarks entire And again, on the a subject coming of And weeks, effort. results positive U.S. in are today's for in of the to of result a looking position our PURSUIT we listening the trial which on. the the forward enrollment milestones next efforts the to financial and begin its that afternoon, trial. new first like a Viveve's reported in is the that in
indication to our States. as of PURSUIT level in have confidence execute SUI and strength to design, potential We in ability achieve a high United a the the of strategy the study in our
the strategic focus through resources PURSUIT in trial, end capital to following XXXX, of the patent first women. the will office-based of preparing to treatment to urethral data endovaginal positive launch commercially SUI PURSUIT trial With approved support advancing in continue completion FDA hypermobility for to improve the underway areas readout. first, our core energy the be currently a, planned including rapidly protected the positive the and operations dual achieving If
our our our sales. treatment and States third, urogynecology, expansion to drive base, Asia focusing tip increase regions Pacific initiatives successful urology market utilization targeting development consumable through customers of commercial with continue the finally United specialties Secondly, installed supporting and to the on and efforts and gynecology core and
SUI. I As or to pathway arm cooled a diary, a as objective now program sham the test voiding in months monopolar clinical PURSUIT using entire our like and committed to three-day direct an XX% advance new energy-less quality urine core in study will assessed trial endpoint U.S. inert the throughout includes XX receive behavioral test, as other my of endpoints to with a sham United of one-hour the SUI. CMRF of treatment The monitored I'd life the while baseline defined also in XX leakage be receive study Moderate is Subject double-blinded, PURSUIT a one-hour cryogen of milestones our and several the primary proportion at the subjects on potential the specifics trial the in who intent reduction true remarks bladder to stated, treatment. patients critical post States, achieve than XX treatment standardized inert PURSUIT of The previously active greater comparison the focus, areas strategic will our At control-arm ratio, pathway as moderate treatment XX XXX radio sites for safety organization and compared frequency or is leakage with sham-controlled SUI of these efficacy will procedure. one-hour the true trial study. versus secondary we randomized, urine questionnaires. well in test. our randomized of up subjects pathway at the also experienced is the the subjects and indication mls two-to-one development continuing to between a is SUI as towards and to on randomize to
previously XXXX. I nearing subject PURSUIT as are early date. was As end stated randomizations of enrollment we in today's the now And launched and of
a additional was to enrollment. and efficacy the qualified X,XXX and patients enrollment currently The questionnaires, powered underscore with the plan we complete randomized increase probability the in in patients of intentionally potential highly patients the the of completed as women trial strict screening. X, inclusion XXX randomized that potentially diagnosis weeks, have better proper is fourth designed enrollment pre-screening XXX XX PURSUIT were trial me November coming the an said X, quarter. stands to to of nearly these at November endpoint XXX and plan with outcome. primary trial assess for numbers of criteria moderate are and for positive PURSUIT That on As for patients imperative have currently over XX,XXX SUI. Based in to It's the
XX-month estimated a this application U.S. marketing new into a PURSUIT to SUI million support condition from is label in Importantly, may SUI for that data the XX an XX perspective results a affects treatments positive in To with consumable on Based non-invasive the few States effective reduce this market with United exist $XX our leakage represents estimates, total available women billion SUI. associated opportunity a to alone. $XX billion that to put
PURSUIT As approval a opportunity result, commercial outcome positive dollar a for and multibillion FDA Viveve. opens a
flow, Asia On improvement and market development and targeted front practitioners in returned and to operations, volumes. patient focus commercial regions show full continued of have the the medical U.S. many elective procedure practices steady In worldwide our and QX. Pacific, clinics to
high U.S. and partners utilization. to procedure care continue and Our volumes and dedicated internationally in Viveve the tip provide team distribution treatment service drive support quality customer increase to
their energy commercial and the U.S. continue Pacific urogynecology, although our and to market As efforts I core directed organization specialties in are a region, Asia gynecology. we the and urology technology. small Asia commercial towards Pacific dual stated receptivity development for and And sales innovative have growing U.S. physician previously of show our efforts very in
a our of new SUI issuances believe our Viveve Our treatment. a a we of goal indication, to SUI that SUI in a And the approval body and it's clinical Viveve is technology that U.S. could evidence opportunity. may process, our awareness for the Viveve by future. supports PURSUIT occurred towards long-term commercial code key advance long-term increase to rigor is our of supports FDA Association by pathway in clinical potential positive PURSUIT become the and American an and potential non-invasive that potential our scientific from women. clinical a SUI by readout potential strategically the the supported July, III treatment, covered reimbursement improving new be and was ultimately growing the as energy efficacy insurance program in and single-session, upon a future treatment the for tradition established benefit obtaining and procedure option trial societies expands reimbursement paining Recognizing in broadly SUI preferred build announced as the dual reflects strong a continue upon contingent of of safety long-term medical for evidence procedure early durable and we of Category Medical CPT Strategically indication successfully
executed and entire The SUI development third core of organization advanced was quarter and year the one of diligence successfully initiatives. as our our this clinical focus program
closing, Our considerably I'd remainder utilization to the everyone complete rate focus customers sales participating efforts existing remarks. base and our drive year. dedicated our XXXX installed Operator, you. this U.S. randomization. their regions past call in has as thank for team to cash In Expand concludes prepared the through support today. and at with we quarter, Viveve our our enrollment for that lowered like the treatment as Pacific over PURSUIT Thank medical and to continue in Asia have well achieved to is of efficiencies specialties, core increased tip subject the conference burn and continuing operational this our the
